ライフサイエンスコーパス: clinical efficacy

1 ment; however, the study was not powered for clinical efficacy.

2 table T cell targets and may help to predict clinical efficacy.

3 eric antigen receptor (CAR) shows remarkable clinical efficacy.

4 received regulatory approval or demonstrated clinical efficacy.

5 ntended mechanism of action, and encouraging clinical efficacy.

6 eting IL-23 and IL-17 have shown significant clinical efficacy.

7 cificity, "off-target" toxicity, and limited clinical efficacy.

8 nicotine vaccine formulations to move toward clinical efficacy.

9 ce molecules have thus far failed to achieve clinical efficacy.

10 ng developed, the first of which are showing clinical efficacy.

11 for antibodies that have already shown some clinical efficacy.

12 ts where NK cells are partly responsible for clinical efficacy.

13 ve been developed and demonstrate remarkable clinical efficacy.

14 ansplant recipients, demonstrated safety and clinical efficacy.

15 escaping vectors are important for improving clinical efficacy.

16 therapeutic monoclonal antibodies has shown clinical efficacy.

17 R monoclonal antibody that has shown limited clinical efficacy.

18 sibility, safety, and strong indications for clinical efficacy.

19 candidates is often required for predicting clinical efficacy.

20 n amyotrophic lateral sclerosis did not show clinical efficacy.

21 directed toward this pathway show promising clinical efficacy.

22 oxidized by CYP3A4, thereby extending their clinical efficacy.

23 these circuits may underlie this plateau in clinical efficacy.

24 ent, suggesting that resistance limits their clinical efficacy.

25 ), and recent studies have suggested similar clinical efficacy.

26 ical trials, however, drug resistance limits clinical efficacy.

27 mmune responses and contribute to their full clinical efficacy.

28 25 mAbs on hDCs that may contribute to their clinical efficacy.

29 are needed to assess long-term toxicity and clinical efficacy.

30 ion has resulted in substantial increases in clinical efficacy.

31 e emergence of drug resistance hampers their clinical efficacy.

32 in vitro, there are few data supporting its clinical efficacy.

33 of prostate cancer is the marginal, if any, clinical efficacy.

34 ination during chemotherapy are required for clinical efficacy.

35 easibility, safety and strong indications of clinical efficacy.

36 therapeutics, substantially improving their clinical efficacy.

37 novel long-acting A2A agonists with improved clinical efficacy.

38 often translating into major improvements in clinical efficacy.

39 er long-term studies are warranted to assess clinical efficacy.

40 wed considerable variability that may impact clinical efficacy.

41 or T-cell receptors (TCRs) has demonstrated clinical efficacy.

42 ion and antinociceptive tolerance, limit its clinical efficacy.

43 ting, novel mechanisms of action, and higher clinical efficacies.

44 was suspended in 136 cases (mostly owing to clinical efficacy [38.2%], inefficacy [26.5%], and ADRs

45 Twenty-five of the 38 (66%) examined clinical efficacy, 7 (18%) evaluated longer follow-up, a

46 The clinical efficacy (99.2% vs 98.8%) and serious adverse e

47 r design that compared the pharmacokinetics, clinical efficacy, adverse events, or immunogenicity of

48 l three agents exhibit in vitro activity and clinical efficacy against MRSA.

49 participants, 209 (80%) were included in the clinical efficacy analysis (140 START, 69 TAU).

50 Few differences were found in clinical efficacy and acceptability between the differen

51 gative infections and the adequacy of GNC on clinical efficacy and all-cause mortality in the telavan

52 s we speculate that it may indicate a better clinical efficacy and be a better choice than current tr

53 However, demonstrating the clinical efficacy and cost effectiveness of these medici

54 CT and CMR will require further evidence of clinical efficacy and cost effectiveness.

55 We aimed to establish the clinical efficacy and cost-effectiveness of BA compared

56 Clinical efficacy and cost-effectiveness were examined f

57 vo cellular kinetic analyses to characterize clinical efficacy and CRS severity associated with CTL01

58 hese cells and develop strategies to enhance clinical efficacy and extend this therapy to other malig

59 rass pollen extracts resulted in significant clinical efficacy and has been shown to be a safe treatm

60 eclinical development hinders predictions of clinical efficacy and identifying factors that underlie

61 Although definitive clinical efficacy and long-term safety data are still ne

62 in the management of PAH patients; however, clinical efficacy and long-term tolerability of some pro

63 lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain.

64 terol concentrations achieved at 4 weeks and clinical efficacy and safety in the FOURIER trial of evo

65 We assessed the clinical efficacy and safety of a Russian-backbone live

66 ional research is necessary to determine the clinical efficacy and safety of CMV suppression in this

67 ation may be a promising strategy to improve clinical efficacy and safety of current BMP therapeutics

68 Conclusion The durable clinical efficacy and safety of MR imaging-guided HIFU w

69 The aim of this study was to evaluate the clinical efficacy and safety of Phleum pratense subcutan

70 We assessed the clinical efficacy and safety of the combination of fosfo

71 at induce immunologic tolerance and enhanced clinical efficacy and safety over that noted for subcuta

72 imer's disease and examines the evidence for clinical efficacy and the major problems with safety-i.e

73 To evaluate the clinical efficacy and tolerability of intravenous (i.v.)

74 The clinical efficacy and toxicity of amiodarone may be dete

75 in lung transplant recipients, evaluates the clinical efficacy and toxicity of the various antifungal

76 Many studies have elucidated the clinical efficacy and underlying mechanisms of MSCs in i

77 rtain, and more definitive conclusions about clinical efficacy and utility will require comparison wi

78 -density lipoprotein cholesterol reductions, clinical efficacy, and adverse events and the relevance

79 System performance, clinical efficacy, and safety events were assessed out t

80 eceptor (A2A) agonists is critical for their clinical efficacy, and we sought to better understand ho

81 We propose that for potential clinical efficacy, antivirals should be evaluated using

82 nkage, so new biomarkers that correlate with clinical efficacy are needed.

83 eral devices are available, data about their clinical efficacy are scarce.

84 d toxicity studies-which, in addition to pre-clinical efficacy, are critical for partnering with Big

85 these pharmaceuticals demonstrate a limited clinical efficacy as multiple Gq-coupled receptor subtyp

86 However, these drugs have shown limited clinical efficacy as single agents in small-cell lung ca

87 lving allergen immunotherapy (AIT) products, clinical efficacy assessment is currently based on doubl

88 Clinical efficacy assessments included event free surviv

89 For each, clinical efficacy at test of cure and all-cause mortalit

90 To definitively explore the potential for clinical efficacy at well-tolerated dosing schedules req

91 However, crucial concerns regarding safety, clinical efficacy, best setting, and cost-effectiveness

92 Despite promising clinical efficacy, both innate and acquired resistance o

93 roxyurea provides SCA-related laboratory and clinical efficacy, but optimal dosing and monitoring reg

94 Trimethoprim-sulfamethoxazole retains clinical efficacy, but resistance rates are increasing i

95 tive value of cell chemosensitivity test for clinical efficacy, cancer cells were suggested to be enc

96 cleared drugs, but have not yet improved the clinical efficacy compared to the non-encapsulated drug.

97 y, the large cell number required to achieve clinical efficacy constitutes an important limitation.

98 eeded World Allergy Organization-established clinical efficacy criteria (>/=20% improvement vs placeb

99 Clinical efficacy data showed a significant improvement

100 inase inhibitors of EGFR, which display poor clinical efficacy despite overexpression and/or mutation

101 The clinical efficacy displayed by ibrutinib in chronic lymp

102 sunitinib treatment breaks are feasible and clinical efficacy does not seem to be compromised.

103 ited data from case-control studies indicate clinical efficacy equivalent to the proportion seroconve

104 of poliomyelitis in Nigeria and to calculate clinical efficacy estimates for the oral poliovirus vacc

105 tin sulfate preservative free showed similar clinical efficacy, evaluated with OSDI score, TBUT and S

106 Three BKIs were then selected for safety and clinical efficacy evaluation in the calf model for crypt

107 hlight AIT-related aspects of public health, clinical efficacy evaluation, mechanisms, development of

108 We present the 1-yr results of clinical efficacy for 3 caries management options for oc

109 ivir, SCY-635, and NIM811) have demonstrated clinical efficacy for the treatment of hepatitis C infec

110 Clinical efficacy has been demonstrated with antibodies

111 Significant clinical efficacy has been observed for all of these con

112 To date, limited clinical efficacy has been observed with either Src or m

113 apy has been available for 20 years, yet its clinical efficacy has never been conclusively demonstrat

114 can unleash a T-cell response, and although clinical efficacy has proven elusive, therapeutic target

115 Findings suggest that: (1) drugs with known clinical efficacy have consistent effects on disease rel

116 cting at the GLP-1 receptor, although having clinical efficacy, have been associated with severe adve

117 Clinical efficacy (ie, survival free of stroke, rehospit

118 ffects of QGE031 with those of omalizumab on clinical efficacy, IgE levels, and FcepsilonRI expressio

119 s allergens for the optimum dose in terms of clinical efficacy, immunogenicity and safety.

120 We compared the clinical efficacy in 2016, of 133 SLIT with 46 SCIT, 351

121 We compared the clinical efficacy in 2017, of 112 SLIT in the third trea

122 to develop architectures that enable robust clinical efficacy in additional tissues.

123 Although corticosteroids have proven clinical efficacy in asthma, many asthmatic inflammatory

124 RAF inhibitors (BRAFi) have shown remarkable clinical efficacy in BRAF mutant melanoma patients.

125 cific BRAF(V600E) inhibitor, has significant clinical efficacy in BRAF(V600E)-positive melanomas, but

126 ional immune suppressive agents have limited clinical efficacy in chronic GVHD, and prolonged immune

127 ly antagonize the AR may contribute to their clinical efficacy in CRPC.

128 of the CDK4/6 cell-cycle kinases have shown clinical efficacy in estrogen receptor (ER)-positive met

129 in patients with solid cancers, but data on clinical efficacy in leukemias are sparse.

130 Despite its impressive clinical efficacy in many patients, intrinsic and acquir

131 oncogenic BRAF V600E, have shown significant clinical efficacy in melanoma patients harboring this mu

132 n genetic abnormality in melanoma, has shown clinical efficacy in melanoma patients, response is, inv

133 ly human CTLA-4-specific mAb, showed durable clinical efficacy in metastatic melanoma; its mechanism

134 ide is an immunomodulatory drug (IMiDs) with clinical efficacy in multiple myeloma (MM) and other lat

135 Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell n

136 Inhibition of the JAK/STAT pathway has clinical efficacy in multiple preclinical models of MS,

137 Specific BRAF and MEK inhibitors have shown clinical efficacy in patients for the treatment of BRAF-

138 r the ligand or receptor, have shown notable clinical efficacy in patients with a variety of cancers,

139 4A1 may be a predictive marker of vitamin D3 clinical efficacy in patients with advanced prostate can

140 Dabrafenib plus trametinib has modest clinical efficacy in patients with BRAF inhibitor-resist

141 pha such as estradiol (E2) have demonstrated clinical efficacy in patients with heavily treated breas

142 ls compete with other lymphocytes to improve clinical efficacy in patients with refractory AML.

143 sly reported that CTL019 achieved impressive clinical efficacy in patients with relapsed/refractory B

144 SLIT in the second treated year showed good clinical efficacy in reducing symptoms and SMS of JCP, a

145 SLIT in the third treated year showed good clinical efficacy in reducing symptoms and TNSMS of JCP,

146 oxviral-based cancer vaccine, have suggested clinical efficacy in some patients with breast, ovarian,

147 ssessed safety outcomes for all patients and clinical efficacy in the largest patient subgroup, those

148 rned from these models to accurately predict clinical efficacy in the later phase testing of new chem

149 Ueq/ml showed both immunological effects and clinical efficacy in the TNPT compared with placebo.

150 Cladribine has moderate clinical efficacy in the treatment of ECD and can be con

151 rus (HBV) infection, but data to support its clinical efficacy in this setting are limited.

152 ibitory receptor blockade, have demonstrated clinical efficacy in treating tumors refractory to conve

153 chemotherapy did not translate into enhanced clinical efficacy including the role of the enhanced per

154 IASD at 6 months, together with measures of clinical efficacy, including functional capacity and cli

155 ome was discontinuation of all ISDs owing to clinical efficacy, inefficacy, adverse drug reaction (AD

156 onse inhibition (Stop Signal Task [SST]) and clinical efficacy (Investigator Rated Conners Adult ADHD

157 rily cytostatic, not cytotoxic, the observed clinical efficacy is a reflection of disease stabilizati

158 Clinical efficacy is associated with improvement of baso

159 e for only a subset of beta-blockers showing clinical efficacy is in heart failure, where members of

160 While conceptually attractive, clinical efficacy is lacking given several key challenge

161 rum, ribosome-targeting antibacterials whose clinical efficacy is seriously threatened by multiple re

162 Although demonstration of clinical efficacy is still well behind the gene therapy

163 reatment of influenza pathologies, for which clinical efficacy may have been limited owing to poor bi

164 T-cell immunotherapy can produce remarkable clinical efficacy, most patients do not achieve durable

165 ivo efficacy in experimental models (n = 4), clinical efficacy (n = 2), taste (n = 2), or compliance

166 h more research is needed to establish their clinical efficacy, novel delivery systems will allow for

167 g IL-23, IL-17A, or IL-17RA, consistent with clinical efficacy observed in psoriasis patients.

168 y, 2001, and December, 2012, to estimate the clinical efficacies of all four OPVs in use and combined

169 The clinical efficacies of long-acting GLP-1 derivatives str

170 This study demonstrates better clinical efficacy of 100 ms compared to 30 ms treatments

171 We compared the clinical efficacy of 191 SLIT with 48 SCIT, 191 primary

172 This study does not support clinical efficacy of a bradykinin B2 receptor antagonist

173 aim of the present study was to evaluate the clinical efficacy of a fixed combination of xanthan gum

174 The demonstrated clinical efficacy of a recombinant vesicular stomatitis

175 Finally, the clinical efficacy of a suppository formulation containin

176 al responses to vaccines and may predict the clinical efficacy of a therapeutic vaccine.

177 To assess the safety and clinical efficacy of achieving a very low (<30 mg/dL) le

178 Here we aim to further document the clinical efficacy of administered IVIG therapy in a comp

179 Finally, given the clinical efficacy of adrenocorticotropin in joint diseas

180 rticular malignancies, as highlighted by the clinical efficacy of agents that target nuclear hormone

181 globally harmonized method for analysing the clinical efficacy of AIT products in RCTs is required.

182 Our data may explain the poor clinical efficacy of anti-myostatin approaches in severa

183 Given the clinical efficacy of anti-NGF monoclonal antibody (mAb)

184 lanoma-PD-1 might contribute to the striking clinical efficacy of anti-PD-1 therapy.

185 bility, resistance-associated mutations, and clinical efficacy of antibiotic therapy, identified via

186 clinical assessment of safety and potential clinical efficacy of autologous CMV-specific T-cell ther

187 y significant difference was detected in the clinical efficacy of Biodentine/Fuji IX when used as ind

188 rmine the extra costs associated with or the clinical efficacy of biological mesh materials for the r

189 Investigation of the clinical efficacy of bortezomib administration in congen

190 cell landscape in cancer and may enhance the clinical efficacy of cancer therapy.

191 w and readily available means to enhance the clinical efficacy of CB HCT.

192 Clinical efficacy of CC-115 was demonstrated in 8 patien

193 These data rationalize the observed clinical efficacy of ceftazidime/avibactam plus aztreona

194 alaria infection (CHMI) study to compare the clinical efficacy of ChAd63-MVA CS with ChAd63-MVA ME-TR

195 However, the clinical efficacy of checkpoint blockade depends upon in

196 The clinical efficacy of chimeric antigen receptor (CAR)-red

197 that this activity might underlie the unique clinical efficacy of clozapine.

198 may be substantial gender differences in the clinical efficacy of commonly prescribed 5-HT-active dru

199 The findings do not support a clinical efficacy of CRF1 blockade in stress-induced alc

200 worsens their quality of life and limits the clinical efficacy of current therapies.

201 ts by deep brain stimulation may subvert the clinical efficacy of deep brain stimulation.

202 Genotypes of CYP2B6 had an interaction with clinical efficacy of docetaxel and thiotepa on metastati

203 t EMMA is a feasible platform for estimating clinical efficacy of drugs and inclusion criteria screen

204 bers play in human disease and we review the clinical efficacy of drugs that block CD28 ligands.

205 Clinical trials have demonstrated the clinical efficacy of early ART; however, these trials ma

206 Acquired resistance compromises the clinical efficacy of EGFR inhibitors during long-term tr

207 blasts, not cytotoxicity, seems to drive the clinical efficacy of enasidenib.

208 Accurate preclinical predictions of the clinical efficacy of experimental cancer drugs are highl

209 It has been proposed that the clinical efficacy of flecainide in CPVT is because of th

210 To assess the clinical efficacy of FOLFOXIRI-Bev, including outcomes a

211 ate protocol development) will determine the clinical efficacy of fosfomycin as step-down oral therap

212 progress has been made in demonstrating the clinical efficacy of harnessing the immune system to tre

213 These benefits might underlie the clinical efficacy of HFNC.

214 inical rationale to immediately evaluate the clinical efficacy of ibrutinib in patients with PDAC.

215 The clinical efficacy of immune cytokines used for cancer th

216 umor microenvironment, which correlates with clinical efficacy of immunotherapies.

217 Studies reporting the clinical efficacy of IPV were also reviewed.

218 ger trials of longer duration to measure the clinical efficacy of itraconazole, especially relative t

219 apeutic intervention, as demonstrated by the clinical efficacy of kinase inhibitors in kinase-mutant

220 The main prerequisite for clinical efficacy of L-asparaginases is micromolar KM fo

221 vide preliminary evidence for the safety and clinical efficacy of long-term, low-dose plerixafor in W

222 between baseline blood eosinophil count and clinical efficacy of mepolizumab in patients with severe

223 nward clinical investigations to examine the clinical efficacy of minocycline treatment regimens agai

224 fety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusin

225 n approach to improve effector functions and clinical efficacy of next-generation IgG1-based therapeu

226 overing a potential explanation for the poor clinical efficacy of Notch inhibitors observed in this s

227 Best evidence of the clinical efficacy of novel immunologic approaches using

228 Athough the clinical efficacy of oncolytic viruses has been demonstr

229 Clinical efficacy of PD-1/PD-L1 targeting relies upon th

230 Clinical efficacy of pollen allergen immunotherapy (AIT)

231 espite better pharmacodynamic properties and clinical efficacy of prasugrel compared with clopidogrel

232 Any RCT comparing mortality or clinical efficacy of prolonged (continuous or >/=3 h) ve

233 The primary objective was to assess the clinical efficacy of Ragweed MATA MPL (short ragweed pol

234 objectives included patient convenience and clinical efficacy of self-administration.

235 The purpose of this study is to clear the clinical efficacy of SLIT by comparing with other therap

236 We reported the clinical efficacy of SLIT in the first and the second tr

237 The purpose of this study is to clear the clinical efficacy of SLIT in the second treated year by

238 The purpose of this study is to clear the clinical efficacy of SLIT in the third treated year by c

239 to accelerate wound healing and enhance the clinical efficacy of stenting.

240 However, the clinical efficacy of such new treatment requires further

241 ue, which may be important in monitoring the clinical efficacy of supporting therapy.

242 Drug resistance invariably limits the clinical efficacy of targeted therapy with kinase inhibi

243 rinciple study, we demonstrate the potential clinical efficacy of the immunosensor for monitoring of

244 [2.0-7.8] to 1.0 [0.4-1.6] g/d), indicating clinical efficacy of the therapy.

245 atform to improve the antitumor activity and clinical efficacy of therapeutic antibodies.

246 n is necessary in order to prove the overall clinical efficacy of these devices in refractory cardiog

247 The clinical efficacy of these drugs is strongly linked to t

248 stance mechanisms is crucial to optimize the clinical efficacy of these drugs.

249 in diverse, potentially redundant ways, the clinical efficacy of these inhibitors as monotherapies h

250 However, the clinical efficacy of these inhibitors can be improved by

251 qualified for a strong rating supporting the clinical efficacy of these materials for periodontics an

252 The clinical efficacy of these two treatment modalities appe

253 date the molecular mechanisms underlying the clinical efficacy of tofacitinib in patients with psoria

254 is study was to determine safety and midterm clinical efficacy of transcatheter PVL closure using an

255 Furthermore, they suggest that clinical efficacy of treatments for FGFR1-driven lung ca

256 In this randomized, split-mouth trial, the clinical efficacy of two different photoablative dental

257 We investigated the clinical efficacy of vandetanib when used in combination

258 d sequestrants (BAS) reduce LDL-C, yet their clinical efficacy on CAD remains controversial.

259 mized trial is required to adequately define clinical efficacy, optimal post-procedure medical therap

260 r of sufficiently long duration to establish clinical efficacy or assess safety.

261 For the clinical efficacy outcomes (change in NIHSS score at 24

262 HIV-1 vaccine concepts have been tested for clinical efficacy over the past 30 years.

263 However, the decline in clinical efficacy over time in many patients suggests th

264 TOR inhibitors have failed to produce useful clinical efficacy, potentially because mTOR is also crit

265 d adolescents 12 years of age and older, the clinical efficacy, safety, and tolerability of omalizuma

266 acceptable toxicity profile and significant clinical efficacy, single-agent brentuximab vedotin is a

267 m cells are emerging in the field, but their clinical efficacy still needs to be defined in future tr

268 ined treatment exhibited higher DRs owing to clinical efficacy than other ISDs in monotherapy.

269 owed that all biological agents have greater clinical efficacy than placebo.

270 d bivalent OPV (29.5%, 20.1-38.4) had higher clinical efficacy than trivalent OPV (19.4%, 16.1-22.8).

271 s, but also importantly define parameters of clinical efficacy that justify further investigation in

272 ass of therapeutic modalities with promising clinical efficacy that requires modification or formulat

273 Despite impressive clinical efficacy, the general application of current CA

274 Although TKIs have demonstrated good clinical efficacy, the lack of complete responses, the c

275 d clinical use of AGs strongly reduced their clinical efficacy through the selection of resistant bac

276 arly-onset/comorbidity cluster had the least clinical efficacy to treatments (eg, -0.076% change in F

277 of of concept supporting the initiation of a clinical efficacy trial in patients with platinum-sensit

278 Several vaccine clinical efficacy trials are approaching completion, and

279 cal sleeve gastrectomy (VSG), a surgery with clinical efficacy very similar to that for RYGB, in whol

280 Clinical efficacy was associated with decreased prolifer

281 Clinical efficacy was evaluated at baseline and weekly i

282 The clinical efficacy was evaluated with quality of life (QO

283 The clinical efficacy was evaluated with symptom scores and

284 The clinical efficacy was evaluated with symptom scores, tot

285 al therapeutic agents, however their in vivo clinical efficacy was limited.

286 Clinical efficacy was maintained at 24 weeks in 0% and 4

287 Preliminary clinical efficacy was noted in five patients (two partia

288 Early evidence of clinical efficacy was observed.

289 rms were not the same, neither mortality nor clinical efficacy was reported, only pharmacokinetic or

290 Clinical efficacy was the most frequent cause for ISD di

291 and safety were confirmed and indications of clinical efficacy were identified.

292 and safety were confirmed and indications of clinical efficacy were identified.

293 ologic hurdles that must be addressed before clinical efficacy will be known.

294 INTERPRETATION: On the basis of the improved clinical efficacy with a manageable safety profile, the

295 This regimen has shown promising clinical efficacy with acceptable tolerability in chemot

296 This regimen has shown promising clinical efficacy with acceptable tolerability in chemot

297 Despite encouraging clinical efficacy with these agents, in many patients re

298 otency observed in vitro has translated into clinical efficacy, with HCV RNA declining by ~3-4 log10

299 Both SCIT and SLIT showed good clinical efficacy without significant difference in ever

300 Both SCIT and SLIT showed good clinical efficacy without significant difference in ever